Dr. Pinter-Brown on Treatment Expectations in CTCL

Lauren Pinter-Brown, MD
Published: Tuesday, Apr 02, 2013

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses physician and patient expectations when treating cutaneous T-cell lymphoma (CTCL).

As with other oncologic conditions, if a patient is being treated with a drug and progresses, it is obvious that the drug is ineffective. In patients with CTCL, physicians have to be aware of the time to response for particular treatments, as they're not identical.

In the case of bexarotene, the time to response is four months, which causes physicians and patients to set appropriate expectations as the patient's condition will not worsen but it will not get better for many months. Fortunately, monitoring CTCL does not require scans or blood tests: physicians simply have to monitor skin lesions as time passes.

Lauren Pinter-Brown, MD, Clinical Professor, Department of Medicine, Hematology-Oncology, University of California, Los Angeles, discusses physician and patient expectations when treating cutaneous T-cell lymphoma (CTCL).

As with other oncologic conditions, if a patient is being treated with a drug and progresses, it is obvious that the drug is ineffective. In patients with CTCL, physicians have to be aware of the time to response for particular treatments, as they're not identical.

In the case of bexarotene, the time to response is four months, which causes physicians and patients to set appropriate expectations as the patient's condition will not worsen but it will not get better for many months. Fortunately, monitoring CTCL does not require scans or blood tests: physicians simply have to monitor skin lesions as time passes.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Moving Forward From the Status Quo for the Treatment of Soft Tissue Sarcoma: Key Questions and New Answers to Optimize OutcomesOct 31, 20182.0
Hematology Briefings™: Advancing Care and Improving Outcomes for Patients With Pyruvate Kinase DeficiencyOct 31, 20181.0
Publication Bottom Border
Border Publication
x